The U.S. Food and Drug Administration (FDA) has granted approval for Gilead Sciences’s Hepcludex, an experimental drug designed to treat chronic hepatitis delta virus (HDV). This rare and severe liver disease, which exclusively affects individuals already living with hepatitis B, can lead to organ failure, cancer, scarring, and death. Until this recent regulatory action, there were no FDA-approved therapies available for patients suffering from this condition.
The regulatory decision for the Chronic Hepatitis Delta Virus treatment was supported by data from a late-stage trial. Results indicated that approximately 48% of patients receiving the therapy experienced meaningful improvement after 48 weeks of administration, compared to 2% of patients whose treatment was delayed. Data further demonstrated that the virus became undetectable in participants as they continued their course of Hepcludex.
As a once-daily injection, the drug functions by preventing the virus from entering liver cells, thereby inhibiting the spread of the viral infection. The FDA utilized its accelerated approval pathway to authorize the treatment, a mechanism intended to expedite the availability of medical interventions for serious diseases that lack adequate alternatives.
While the approval of Hepcludex addresses a significant medical necessity, the regulatory body has mandated a boxed warning for the medication. This is the most serious warning issued by the FDA, alerting healthcare providers that discontinuation of the treatment may result in severe, potentially life-threatening flare-ups of both hepatitis D and hepatitis B. This risk is particularly pronounced in patients who have already developed advanced liver scarring.
As part of the approval process, the manufacturer has committed to conducting long-term studies to confirm the full clinical benefits of the medication. This liver disease therapy previously received full approval in Europe in 2023 under a different dosage regimen. Current estimates suggest that between 40,000 and 80,000 individuals in the United States are living with chronic hepatitis delta virus.
